JCO Comments and Controversies piece out. Provides rationale for PRESTIGE and MAGESTIC trials to come.
Thanks @UroAlsyouf@siadaneshmand@LuciaNappi4
DOI: 10.1200/JCO.22.02002
Case for pRPLND as chemo-sparing approach in CSII NS becoming stronger. @moosemousa@RHamiltonUrol#AUA2023 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR METASTATIC NONSEMINOMATOUS GERM CELL TUMOR:
Testis cancer oral abstracts ASCO pick up nicely on two emerging likely practice changing themes. miR371 (@LuciaNappi4) and primary RPLND in early regional seminoma (T. Tandstad). Can't wait
Well. . . This is a bit awkward. ChatGPT appears to be as good at poetry as it is at understanding clinical trial design, conduct, actual patient impact and cogent debate
While not a lot of new information, the article is important in that it reiterates the high baseline of CVD risk factors (with or without cisplatin) for men as they move into their 40s/ 50s. Should have low threshold for management of HTN, dyslipidemia, obesity, energy balance
Nice AUA abstract by Candelas-Gomez, Hamilton, Jewett et al re Canadian 2nd opinion in GCT. Mirrors England SWENTOTECA German efforts at hub and spoke care delivery
Emerging Clinical Decision-Making Tools in Clinical Stage I and IIA/B Germ Cell Tumors—What Are the Targets?
ASCO Daily News piece out today with colleagues @LuciaNappi4@siadaneshmand and C. Kollmannsberger